MicroRNAs: immune modulators in cancer immunotherapy

Xing, Yun; Wang, Zhiqiang; Zhou, Lu; Xia, Jie; Xie, Zhangjuan; Jiao, Mengxia; Liu, Ronghua; Chu, Yiwei

doi:10.1093/immadv/ltab006

Cited by 27 publications

(19 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 In vitro studies showed that blockade of miR-15a/16-1 decreased the expression of TIM-3, LAG-3 and PD-1 and enhanced functional CD8 + T cells by increasing the expression of mTOR signalling pathway. 49,50 These findings suggest that miR-15a/16-1 as biomarkers of resistance to ICIs in glioma and potential therapeutic targets for improving the sensitivity to ICIs. An interesting study investigated the role of adenosine deaminase acting on RNA-1 (ADAR1) in melanoma immunomodulation.…”

Section: 1mentioning

confidence: 88%

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Alahdal,

Elkord

2023

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundTo date, standardising clinical predictive biomarkers for assessing the response to immunotherapy remains challenging due to variations in personal genetic signatures, tumour microenvironment complexities and epigenetic onco‐mechanisms.Main bodyEarly monitoring of key non‐coding RNA (ncRNA) biomarkers may help in predicting the clinical efficacy of cancer immunotherapy and come up with standard predictive ncRNA biomarkers. For instance, reduced miR‐125b‐5p level in the plasma of non‐small cell lung cancer patients treated with anti‐PD‐1 predicts a positive outcome. The level of miR‐153 in the plasma of colorectal cancer patients treated with chimeric antigen receptor T lymphocyte (CAR‐T) cell therapy may indicate the activation of T‐cell killing activity. miR‐148a‐3p and miR‐375 levels may forecast favourable responses to CAR‐T‐cell therapy in B‐cell acute lymphoblastic leukaemia. In cancer patients treated with the GPC3 peptide vaccine, serum levels of miR‐1228‐5p, miR‐193a‐5p and miR‐375‐3p were reported as predictive biomarkers of good response and improved overall survival. Therefore, there is a critical need for further studies to elaborate on the key ncRNA biomarkers that have the potential to predict early clinical responses to immunotherapy.ConclusionThis review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR‐T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.

show abstract

Section: 1mentioning

confidence: 88%

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Alahdal,

Elkord

2023

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…miRNAs regulate many immune-tumor cell junctions and essential immune response processes ( 178 ). miRNAs have also been discovered to be tumor suppressors or oncogenes, with the ability to control antitumor immunity or crosstalk between cancer cells and their surrounding immune cells ( 179 ). miRNAs can be used as prognostic, diagnostic, and targeted immunotherapeutics based on their specific regulatory role.…”

Section: Role Of Mir-128 In Immune Responses and Immunotherapy In Cancermentioning

confidence: 99%

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

et al. 2023

View full text Add to dashboard Cite

A growing body of evidence has revealed that microRNA (miRNA) expression is dysregulated in cancer, and they can act as either oncogenes or suppressors under certain conditions. Furthermore, some studies have discovered that miRNAs play a role in cancer cell drug resistance by targeting drug-resistance-related genes or influencing genes involved in cell proliferation, cell cycle, and apoptosis. In this regard, the abnormal expression of miRNA-128 (miR-128) has been found in various human malignancies, and its verified target genes are essential in cancer-related processes, including apoptosis, cell propagation, and differentiation. This review will discuss the functions and processes of miR-128 in multiple cancer types. Furthermore, the possible involvement of miR-128 in cancer drug resistance and tumor immunotherapeutic will be addressed.

show abstract

“…As described above, miRNAs play key roles in tumor immunity through their functions in both tumor and immune cells, highlighting their potential in disease classification and as therapeutic agents ( 301 ). Various classes of immunotherapy were shown to impact the miRNA networks in the TME ( 302 – 304 ). In this section, we will highlight the involvement of miRNAs in immunotherapy action mechanisms and discuss opportunities to improve clinical outcomes.…”

Section: Mirnas and Cancer Immunotherapymentioning

confidence: 99%

miR-aculous new avenues for cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

The rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell–derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.

show abstract

MicroRNAs: immune modulators in cancer immunotherapy

Cited by 27 publications

References 110 publications

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

miR-aculous new avenues for cancer immunotherapy

Contact Info

Product

Resources

About